Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™
Boehringer Ingelheim India’s stroke awareness campaign enters the GUINNESS WORLD RECORDS™. Click here to read the press release and find out more.
Search
Jardiance® (empagliflozin) now approved in India for treatment of chronic kidney disease
Jardiance® (empagliflozin) now approved in India
India
In India, Boehringer Ingelheim is one the fastest growing multinational pharmaceutical companies. Find out more about our presence in India here.
Boehringer Ingelheim India recognized as Top Employer 2024
Boehringer Ingelheim India recognized as Top Employer 2024
Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India
Boehringer Ingelheim introduces NexGard SPECTRA® for dogs in India
Boehringer Ingelheim announces appointment of Gagandeep Singh as Managing Director and Head of Human Pharma for India
Boehringer Ingelheim announces appointment of Gagandeep Singh as Managing Director and Head of Human Pharma for India
Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium
Boehringer Ingelheim expands animal health portfolio in India with the launch of NexGard® (afoxolaner) Small and Medium
Boehringer Ingelheim India signs MoU with the Government of Maharashtra, to strengthen stroke care in the state
Boehringer Ingelheim India signs MoU with the Government of Maharashtra, to strengthen stroke care in the state
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management
Boehringer Ingelheim India to sustain growth momentum in 2021, focuses on partnerships in NCD management. Click here to find out more information.
COVID-19 India - supporting community during the pandemic
Boehringer Ingelheim India was amongst the first few companies supporting local authorities in Maharashtra in this crisis. Click here to learn more.
Boehringer Ingelheim announces appointment of Vani Manja as India Country MD
Boehringer Ingelheim has announced that Vani Manja is appointed Country Managing Director for India. Read the press release here and find out more.
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India
Boehringer Ingelheim launches additional heart failure indication for Jardiance® (empagliflozin) in India. Click here to find out and learn more.
COVID-19 Volunteering in India
Learn about our employees in India volunteering during COVID-19, including Rashmi Suvarna, Head of Procurement at Boehringer Ingelheim India.
Boehringer Ingelheim allocates COVID relief fund to support underserved communities and patients in India
Boehringer Ingelheim is making available a Euro One Million COVID relief fund to support underserved communities and patients in India. Learn more here.
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine
Boehringer Ingelheim India launches VAXXITEK® HVT + IBD, globally acclaimed single shot poultry vaccine. Click here to find out and learn more information.
BI India joins forces with PPAM and BMC to Stop Rabies
This initiative will adopt a two-pronged approach of vaccination and education.
COVID-Relief-India-2021
Boehringer Ingelheim prioritises life continuity to the underserved, in addition to medical aid. Click here to find out and learn more information.
Boehringer Ingelheim and IIT Kanpur join hands for social impact
Boehringer Ingelheim India to support Lenek Technologies, a startup incubated at SIIC, IIT Kanpur to improve tuberculosis screening through its innovative handheld X-ray device.
India Factsheet
India Factsheet Updated
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalization for heart-failure and cardiovascular death
EMPEROR-Preserved trial reveals that Empagliflozin reduces the risk of hospitalisation for heart-failure and cardiovascular death. Find out more here.
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug
Boehringer Ingelheim receives ad-interim injunctions against four more domestic pharma companies for patent infringement of its anti-diabetes drug.
Dr. V. Mohan Releases 9-point Action for People with Diabetes
Dr V. Mohan has released a 9-point action plan to ensure health for people with diabetes. Click here to read the press release and find out more.